diarrhea/inflammation

BACKGROUND OF INVENTION Diarrhea is a common illness affecting people of all ages. The loss of fluids through diarrhea can cause dehydration and electrolyte disturbances. In the United Sates, adults have an average of one episode of acute diarrhea each year; diarrhea occurs more frequently in

BACKGROUND OF THE INVENTION Maintaining the well being of the GI tract of a mammal is a very desirable goal. Particularly annoying are inflammatory conditions of the GI tract. Some of the signs of inflammation of the GI tract include acute or chronic diarrhea, soft stools, blood in stool, vomiting,

BACKGROUND OF THE INVENTION EP 419,049, Prasit et al., Mar. 27, 1991, describes a series of quinolin-2-ylmethoxy indoles useful as inhibitors of leukotriene biosynthesis. Examples 1 and 1A therein teach the synthesis of 3-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-

FIELD OF THE INVENTION The present invention relates to 5-ASA derivatives and methods of treating diseases therewith. BACKGROUND OF THE INVENTION Many people suffer from inflammatory bowel disease (IBD). TRD is a generic term used to refer to two inflammatory diseases, ulcerative colitis and Crohn's

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of

This application is a .sctn. 371 of International Application No. PCT/IB2015/056905, filed 9 Sep. 2015, which claims the priority of PCT/CN2015/086995, filed 14 Aug. 2015, and PCT/CN2014/086197, filed 10 Sep. 2014, which are incorporated herein in their entireties. FIELD OF INVENTION This invention

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of

This application is a .sctn.371 of International Application No. PCT/CN2015/089332, filed 10 Sep. 2015, which claims the priority of PCT/CN2014/000834, filed 10 Sep. 2014, which are incorporated herein in their entireties. FIELD OF INVENTION This invention relates to novel compounds which are

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of

FIELD OF INVENTION This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of

This application is a 371 of International Application No. PCT/IB2014/059817, filed 14 Mar. 2014, which claims priority of PCT/CN2014/072449, filed 24 Feb. 2014; PCT/CN2013/090059, filed 20 Dec. 2013; and PCT/CN2013/072683, filed 15 Mar. 2013. FIELD OF INVENTION This invention relates to novel

BACKGROUND The vanilloid receptor 1 (VR1) is the molecular target of capsaicin, the active ingredient in hot peppers. Julius et al. reported the molecular cloning of VR1 (Caterina et al., 1997). VR1 is a non-selective cation channel which is activated or sensitized by a series of different stimuli